Trial · NCT07901153
Platelet-Rich Plasma, Hyaluronic Acid, or Their Combination for Knee Osteoarthritis in Athletes
NCT07901153, Not applicable, Not yet recruiting, University of Sao Paulo General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platelet-Rich Plasma, Hyaluronic Acid, or Their Combination for Knee Osteoarthritis in Athletes. Trials, record NCT07901153. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901153
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platelet-Rich Plasma, Hyaluronic Acid, or Their Combination for Knee Osteoarthritis in Athletes
- NCT number
- NCT07901153
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 300 participants, estimated
- Lead sponsor
- University of Sao Paulo General Hospital
- Conditions
- Knee Osteoarthritis
- Interventions
- Leukocyte-Poor Platelet-Rich Plasma, High Molecular Weight Hyaluronic Acid
- First posted
- 2026-10-28
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in WOMAC Total Score From Baseline to 12 Months | Baseline and 12 months after the intervention | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), validated Brazilian Portuguese version. The WOMAC has 24 items (pain, 5 items; stiffness, 2 items; physical function, 17 items), each scored from 0 (none) to 4 (extreme) on a Likert scale. The total score ranges from 0 to 96 points, and higher scores indicate worse pain, stiffness and physical function (worse outcome). The outcome is the change from baseline to 12 months; a greater reduction indicates greater improvement. Primary comparison: PRP combined with hyaluronic acid versus PRP alone. |
| Secondary | WOMAC Total and Subscale Scores (Pain, Stiffness and Physical Function) | Baseline, 3, 6, 12 and 24 months after the intervention | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), validated Brazilian Portuguese version, compared among the three groups. Total score ranges from 0 to 96; subscales range from 0 to 20 (pain), 0 to 8 (stiffness) and 0 to 68 (physical function). For the total score and all subscales, higher scores indicate worse symptoms and function (worse outcome). |
| Secondary | Knee Injury and Osteoarthritis Outcome Score (KOOS) | Baseline, 3, 6, 12 and 24 months after the intervention | Knee Injury and Osteoarthritis Outcome Score (KOOS), validated Brazilian Portuguese version, five subscales scored separately: pain, other symptoms, function in activities of daily living, function in sport and recreation, and knee-related quality of life. Each subscale ranges from 0 (extreme knee problems) to 100 (no knee problems); higher scores indicate better outcomes. |
| Secondary | Lysholm Knee Scoring Scale | Baseline, 3, 6, 12 and 24 months after the intervention | Lysholm score (0 to 100; higher scores indicate better knee function). |
| Secondary | Tegner Activity Level | Baseline, 3, 6, 12 and 24 months after the intervention | Tegner activity scale (0 to 10; higher levels indicate higher physical and sports activity). |
| Secondary | International Knee Documentation Committee (IKDC) Subjective Knee Form | Baseline, 3, 6, 12 and 24 months after the intervention | IKDC subjective score (0 to 100; higher scores indicate better knee function and fewer symptoms). |
| Secondary | Knee Pain Intensity by Visual Analog Scale (VAS) | Baseline, 3, 6, 12 and 24 months after the intervention | Average knee pain in the previous week on a 0 to 10 visual analog scale (0 = no pain; 10 = worst imaginable pain). |
| Secondary | Patient Global Impression of Improvement (PGI-I) | 3, 6, 12 and 24 months after the intervention | Participant-rated global impression of change on a 7-point scale (1 = very much better; 7 = very much worse). |
| Secondary | Satisfaction With Treatment | 3, 6, 12 and 24 months after the intervention | Participant satisfaction with the treatment received on a 5-point Likert scale (1 = very dissatisfied; 5 = very satisfied). |
| Secondary | Proportion of OMERACT-OARSI Responders | 3, 6, 12 and 24 months after the intervention | Responders defined as improvement of at least 50% and 20 points (0 to 100 scale) in pain or function, or improvement of at least 20% and 10 points in at least two of pain, function and patient global assessment. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901153
GET https://conductscience.org/api/trials/v1/NCT07901153/registered